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Identification of brain antigens 
recognized by autoantibodies 
in experimental autoimmune 
encephalomyelitis-induced 
animals treated with etomoxir or 
interferon-β
Anne Skøttrup Mørkholt1, Kenneth Kastaniegaard1, Michael Sloth Trabjerg1,  
Gopana Gopalasingam1, Wanda Niganze1, Agnete Larsen2, Allan Stensballe  1,  
Søren Nielsen1 & John Dirk Nieland1
Multiple sclerosis (MS) is a neurodegenerative autoimmune disease, where chronic inflammation plays 
an essential role in its pathology. A feature of MS is the production of autoantibodies stimulated by an 
altered-peptide-ligand response and epitope spreading, resulting in loss of tolerance for self-proteins. 
The involvement of autoantibodies in MS pathogenesis has been suggested to initiate and drive 
progression of inflammation; however, the etiology of MS remains unknown. The effect of etomoxir 
and interferon-β (IFN-β) was examined in an experimental-autoimmune-encephalomyelitis (EAE) 
model of MS. Moreover, the impact of etomoxir and IFN-β on recognition of brain proteins in serum 
from EAE rats was examined with the purpose of identifying the autoantibody reactivities involved in 
MS. Animals treated with etomoxir on day 1 exhibited a statistically significantly lower disease score 
than animals treated with IFN-β (on day 1 or 5) or placebo. Etomoxir treatment on day 5 resulted in a 
significantly lower disease score than IFN-β treatment on day 1. After disease induction antibodies was 
induced to a broad pallet of antigens in the brain. Surprisingly, by blocking CPT1 and therewith lipid 
metabolism several alterations in the antibody response was observed suggesting that autoantibodies 
play a role in the EAE animal model.
Multiple sclerosis (MS) is a chronic inflammatory disease of the brain and spinal cord that results in demyelina-
tion, neurodegeneration and axonal loss1. To date, no cure for MS has been identified, and although treatment for 
relapse-remitting MS focuses on reducing disease activity and progression, no treatment for the progressive types 
of MS has been identified2,3. One of the first-line therapies for MS is interferon-β (IFN-β), which functions by 
redirecting immunological responses from pro-inflammatory to anti-inflammatory T cell responses4. However, 
immunomodulatory treatments do not show long-term effects and have no effect on patients entering the pro-
gressive phase of MS2,4,5. B cells are another potential target for treating MS, and several types of anti-CD20 treat-
ments have shown efficacy in clinical trials6. Ocrelizumab is a new recombinant humanized antibody that targets 
CD20 antigen expressed on B cells and has shown efficacy in phase 3 trials for treatment of both relapse-remitting 
MS and primary progressive MS7,8.
Multiple sclerosis as an autoimmune disease
The etiology of MS remains unknown; however, environmental triggers in genetically susceptible individuals have 
been proposed as a model1,9,10. T cells are thought to be activated in the periphery through various mechanisms, 
1Department of Health Science and Technology, Aalborg University, Aalborg, Denmark. 2Department of Biomedicine, 
Aarhus University, Aarhus, Denmark. Anne Skøttrup Mørkholt and Kenneth Kastaniegaard contributed equally to 
this work. Correspondence and requests for materials should be addressed to J.D.N. (email: jdn@hst.aau.dk)
Received: 1 September 2017
Accepted: 19 April 2018
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCieNTifiC RepoRts |  (2018) 8:7092  | DOI:10.1038/s41598-018-25391-y
such as molecular mimicry, by-stander activation and exposure to bacteria present in the colon, and then to 
traffic to the central nervous system with activated B cells and monocytes. For more than two decades, this 
hypothesis has been proposed as the framework for understanding and treating MS as an autoimmune disease9. 
However, studies indicate that the T cell biology in MS is complex and that several T cell types play a role in MS 
pathogenesis11–13.
In recent years, the involvement of B cells and autoantibodies in MS has been re-examined, and they are 
both thought to play a central role in MS pathogenesis due to a correlation between disease progression and 
synthesis of intrathecal antibodies known as oligoclonal bands9,14–17. Nevertheless, limited knowledge is avail-
able about the antibody-antigen response in the brain and its role in disease induction and progression14,18,19. 
However, recent studies found that treatment with ocrelizumab, which functions by depleting CD20-expressing 
B cells, had beneficial effects on primary progressive MS and thereby reinforced the contribution of B cells to MS 
pathogenesis8. Specific posttranslational modifications have been shown to result in the loss of tolerance to the 
modified proteins, thus initiating antibody recognition20,21. A candidate for initiation of such an autoimmune 
response is a posttranslational modification termed citrullination, which naturally occurs on a myelin protein 
known as myelin basic protein (MBP). Citrullination is highly immunogenic, and antibodies against citrulline 
proteins are already used as diagnostic biomarkers in rheumatoid arthritis20,21. However, treating relapses with 
immunomodulatory therapies does not stop progression towards neurodegeneration and axonal loss, and as this 
effect indicates that the causes of lesions and neurodegeneration involve other mechanisms, key questions remain 
unanswered. Mechanisms underlying disease progression are proposed to involve an interaction between oxida-
tive stress, mitochondrial dysfunction, energy deficit and ion channel dysfunction, which are also suggested to 
be involved in neurodegeneration in Alzheimer’s disease (AD), Parkinson’s disease (PD) and amyotrophic lateral 
sclerosis (ALS)22,23.
Multiple sclerosis as a consequence of metabolic dysfunction
The traditional view of MS as a chronic inflammatory autoimmune disease is controversial. Alternatively, MS 
has been proposed to be a consequence of lipid metabolism dysfunction as well as mitochondrial dysfunction24. 
Studies have supported this hypothesis, as they have shown impaired glucose metabolism in MS25,26. Reduced 
glucose metabolism indicates a shift in metabolism towards lipid metabolism, which is consistent with previous 
reports of decreased lipid levels in MS lesions27,28. In addition, research has shown that T cells exposed to stress 
also induce a switch from glucose to lipid metabolism as an energy source, which underpins the importance of 
lipid metabolism in immune cells29. Carnitine palmitoyl transferase 1a (CPT1a) is a key enzyme involved in lipid 
metabolism, as it catalyzes the conversion of acyl-CoA (which is mitochondrial membrane-impermeable) into 
acyl-carnitine (which is mitochondrial membrane-permeable)29 [Mørkholt et al., submitted for publication]. This 
indicates that CPT1a serves as a rate-limiting enzyme in beta-oxidation29,30. CPT1a expression was found to be 
upregulated in MS lesions of the spinal cord31. Additionally, mutations in CPT1a resulting in either 22% activity 
or a dysfunctional molecule were found in two human populations in Canada, namely, the Inuits and Hutterites, 
respectively32–36. The incidence of developing MS was found to be 1/50,000 for the Inuits and 1/1100 for the 
Hutterites, which is rather low compared to the incidence of 1/350 in the Canadian population37,38. These findings 
suggest a role of CPT1a mutations in protecting against the development of MS. Although the particular mecha-
nism involved in the role of CPT1 in MS is unknown, it can be hypothesized that decreased CPT1 activity plays 
a protective role against mitochondrial dysfunction, as CPT1 plays an essential role in energy production from 
lipids, which thereby results in diminished production of reactive oxygen species (ROS). Furthermore, ROS and 
reactive nitrogen species (NOS) are both thought to be mediators involved in demyelination and axonal injury in 
MS and experimental autoimmune encephalomyelitis (EAE)39,40.
Chemical blockage of CPT1 by etomoxir enables a shift in metabolism that favors glucose metabolism rather 
than lipid metabolism as an energy source41–44 [Mørkholt et al., submitted for publication]. This CPT1 antagonist 
inhibits formation of acyl-carnitine, which is necessary for the transport of acyl-CoA into the mitochondria41. 
CPT1 inhibition presents a new treatment strategy that aims at both metabolism and immune system rather than 
focusing solely on inflammation as a therapeutic target. Studies by Shriver et al. and Mørkholt et al. supported 
this new hypothesis by showing that etomoxir treatment resulted in decreased disease activity and inflammation 
and increased remyelination in an EAE mouse model characterized by the expression of hallmarks of MS such as 
demyelination and inflammation11,29 [Mørkholt et al., submitted for publication]. This suggests that etomoxir is 
a novel potential treatment for MS.
This study aimed to investigate the efficacy of etomoxir and IFN-β treatment on the autoantibody response 
in EAE-induced and healthy animals using Western blot analysis and to identify and examine the levels of 
autoantibody reactivity for autoantigens recognized by these autoantibodies by immunoprecipitation and mass 
spectrometry.
Results
Disease score in an experimental autoimmune encephalomyelitis model. The impacts of the two 
treatments (etomoxir and IFN-β) and two treatment time points (days 1 and 5) were compared with those of the 
placebo treatment and control groups (Fig. 1). There were statistically significant differences in the disease score 
between animals treated with etomoxir on day 1 and animals treated with IFN-β on days 1 and 5 and placebo 
(p < 0.05 and p < 0.001). Moreover, animals receiving etomoxir on day 5 exhibited a significantly lower disease 
score than animals treated with IFN-β on day 1 (p < 0.01).
Detection of autoantibodies against brain proteins. Western blot analysis was performed to inves-
tigate the immunoglobulin G (IgG) antibody response against brain self-antigens in EAE-induced rats receiving 
placebo, IFN-β on day 1 or 5, or etomoxir on day 1 or 5 (Fig. 2). Autoantibodies against brain antigens were 
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Figure 1. Mean clinical score for animals in the EAE model; control (C, n = 5), placebo (P, n = 10), IFN-β 
on day 1 (I1, n = 10), IFN-β on day 5 (I5, n = 10), etomoxir on day 1 (E1, n = 10) and etomoxir on day 5 
(E5, n = 10). All data are presented as the mean ± SEM. Results from unpaired t-tests showed a statistically 
significant difference in the disease scores between E1 and I1, I5, and placebo. Treatment on E5 resulted in a 
significantly lower disease score than that on I1. Number of asterisks indicates level of statistical significance 
(*p < 0.05 and ***p < 0.001).
Figure 2. Western blots showing expression of brain antigens recognized by serum-derived antibodies; control 
(C), placebo (P), IFN-β on day 1 (I1), IFN-β on day 5 (I5), etomoxir on day 1 (E1) and etomoxir on day 5 (E5). 
Protein marker positions are indicated to the left (kDa). MBP bands are marked with arrows. Serum samples are 
derived from the same experiment. Each blot represents a sample from the different treatment groups, and blots 
were cropped and processed in parallel (a). Indirect ELISA showing the concentration (µg/ml) of serum-derived 
autoantibodies towards MBP in the presented blots (b). Indirect ELISA showing the concentration (µg/ml) of 
serum-derived autoantibodies towards MBP (c) and albumin (d) in all the animals. Data are presented as the 
mean ± SEM.
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detected in all animals, and interestingly, EAE- induced rats treated with etomoxir on day 1 showed weaker anti-
gen binding than the other treatment groups. All six groups revealed expression of MBP (Fig. 2a). The autoanti-
body response to MBP was validated by ELISA (Fig. 2b and c).
Detection of autoantigens recognized by autoantibodies in the brain. To investigate detection of 
antibodies to brain proteins further, immunoprecipitation was performed, and precipitated proteins were iden-
tified and quantified using label-free mass spectrometry. A Venn diagram of the identified proteins showed a 
high similarity in the number of precipitated proteins between groups (Fig. 3). The highest number of detected 
proteins in a sample was 123; of these proteins, seven were directly related to IgG (these proteins were discarded 
because they could have originated from serum antibodies), and 116 were suggested as self-antigens, including 
MBP and myelin proteolipid protein (PLP).
Interestingly, certain antigens in the control, placebo and treatment groups were highly similar; the lowest 
similarity percentage was 55%. The differences in the relative abundance, which potentially represents the anti-
body response, between the treatment groups and the placebo and control groups were investigated.
There were several significant differences in the quantification of autoantibody reactivity for antigens between 
the treatment groups and the placebo and control groups (Fig. 4, Supplementary Figure S1).
Some of the significant differences between the placebo and treatment groups were found on both treatment 
days (Fig. 5). The levels of relative autoantibody reactivity’s for apolipoprotein E (ApoE), clusterin, plasma pro-
tease C1 inhibitor, and serum amyloid P component (SAP) were all found to be decreased in etomoxir-treated 
animals, whereas antibody reactivity for serum albumin was found to be increased. The same changes were found 
in the control group for plasma protease C1 inhibitor and serum albumin levels. In IFN-β-treated animals, the 
autoantibody reactivity for complement component C9 and gelsolin were decreased, whereas the relative autoan-
tibody reactivity for PLP was upregulated, and only antibody reactivity for complement component C9 was the 
same as that in control animals.
Discussion
The clinical efficacy of the CPT1 inhibitor etomoxir was compared to that of the current first-line treatment 
IFN-β in an EAE model of MS. Animals treated with etomoxir on day 1 had a statistically significantly lower 
disease score at day 11 than animals receiving placebo, IFN-β on day 1 and IFN-β on day 5. Moreover, the group 
treated with etomoxir on day 5 obtained a significantly lower disease score than the IFN-β on day 1 treatment 
group. These lower disease scores obtained after etomoxir treatment indicate that blocking beta- oxidation in the 
mitochondria is a target for treating EAE and potentially MS. This result is consistent with the finding of Shriver 
and colleagues, who showed a beneficial effect of etomoxir treatment in an EAE model29. Furthermore, Bakshi 
et al. found that anti-lipid IgG antibodies were associated with the worsening of brain MRI measurements in 
MS patients45. Gonzalo et al. found significantly increased amounts of autoantibodies to lipoxidized proteins, 
indicating that lipid peroxidation is a pathogenic pathway in MS46. Regarding IFN-β-treated groups, Shirani et 
al. found that IFN-β treatment did not slow the progression of disability in MS patients, which is consistent with 
the findings of the present study5.
Western blot analysis showed weaker antibody signals following treatment with etomoxir on day 1 compared 
to the other treatments. This result could indicate a lower abundance of antibodies in the serum, which could be 
an effect of etomoxir treatment. As the blotting was directed against IgG antibodies, it is important to consider 
that the half-life of these antibodies is four to eight days in mice and could thus be similar in rats47. However, it is 
unlikely that such a decrease in antibody concentration would be substantial enough to have an obvious effect in 
late-treated animals. The high similarity between these potential autoantigens indicated that autoantibodies were 
present even in healthy animals, raising the question of why the autoimmune response was not active in control 
animals. This result could be due to low concentrations of antibodies, low affinity towards the antigen or an intact 
blood-brain barrier (BBB).
In the current study, the placebo group had significantly higher serum concentrations of antibodies against 
positive acute phase reactants (α1-acid glycoprotein, complement component C9, haptoglobin, ceruloplasmin, 
and plasma protease C1 inhibitor) and significantly lower serum concentrations of antibodies against negative 
acute phase reactants (transthyretin and α1-inhibitor-3) than the control group. These findings are consistent 
with the literature48–54. Furthermore, complement component C9 has been found to be directly correlated with 
Figure 3. Venn diagram of the immunoprecipitated proteins identified using mass spectrometry. Number of 
co-identified proteins corresponding to number of autoantibodies and percentages of similarity are shown in 
the treatment groups; control (C), placebo (P), IFN-β on day 1 (I1), IFN-β on day 5 (I5), etomoxir on day 1 (E1) 
and etomoxir on day 5 (E5).
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demyelination of the spinal cord55. A previous study showed elevated levels of hemopexin during the progression 
of disease in the EAE model, which is consistent with our findings56. In this study, EAE was induced by MBP 
suspended in complete Freund’s adjuvant; therefore, an antibody response to MBP was expected and was used as 
a positive control in this model57,58. The autoantibody response to MBP was validated by ELISA. The intensities 
of serum antibodies in the placebo group were consistent with the fact that the placebo group obtained a high 
Figure 4. Significant differences in the relative quantification between the treatment groups and the placebo (P) 
and control (C) groups. Treatments: E1 = etomoxir on day 1; E5 = etomoxir on day 5; I1 = IFN-β on day 1; 
I5 = IFN-β on day 5. SD under 2.0 on log2 scale.  significantly increased or  significantly decreased by at least 
a factor of 2. Number of asterisks indicates level of statistical significance (*p < 0.05 and **p < 0.01). More 
information can be found in Supplementary Figure S1.
www.nature.com/scientificreports/
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disease score, which implies that high levels of positive acute phase reactants and antigens and low levels of neg-
ative acute phase reactants are associated with EAE and possibly MS.
Furthermore, the two etomoxir-treated groups had significantly lower serum concentrations of antibodies 
against ApoE, clusterin, SAP, and plasma protease C1 inhibitor and a significantly higher serum concentration 
of anti-albumin antibody than the placebo group. Studies have shown an association between ApoE and MS59,60. 
Figure 5. Intensity of immunoprecipitated protein for all groups; apolipoprotein E (a), serum amyloid P 
component (b), clusterin (c), serum albumin (d), complement component C9 (e), gelsolin (f) and myelin 
proteolipid protein (g); control (C, n = 5), placebo (P, n = 10), IFN-β on day 1 (I1, n = 10), IFN-β on day 
5 (I5, n = 10), etomoxir on day 1 (E1, n = 10) and etomoxir on day 5 (E5, n = 10). All data are presented 
as the mean ± SEM. Results from the unpaired t-tests showed statistically significant differences in the 
immunoprecipitated protein intensities between P and E1 and E5 (a–d) and between P and I1 and I5 (e–g). 
Number of asterisks indicates level of statistical significance (*p < 0.05, **p < 0.01 and ***p < 0.001).
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7SCieNTifiC RepoRts |  (2018) 8:7092  | DOI:10.1038/s41598-018-25391-y
Of note, Zhao et al. examined the effect of ApoE mimetic peptides in a mouse model of diffuse brain injury 
and found that ApoE mimetic peptides improved memory function and protected against neuronal apoptosis 
by inhibiting the ERK1/2 pathway and Bax expression. Moreover, malondialdehyde content was significantly 
decreased, and superoxide dismutase content was significantly increased61. Pang et al. showed that treatment 
with ApoE mimetic peptides in an experimental model of subarachnoid hemorrhage resulted in reduced deg-
radation of the BBB, which further resulted in less severe brain edema and neuron apoptosis, increased cere-
bral glucose uptake, and improved neurological functions. Moreover, the peptides inhibited cyclophilin, nuclear 
factor-kappaB, interleukin-6, tumor necrosis factor-α, and interleukin-1 and thus inflammation and BBB dis-
ruption62. This finding could indicate that the significant reduction in serum autoantibodies reactivity for ApoE 
resulted in decreased inactivation of ApoE and thereby a lower degree of inflammation, apoptosis and breakdown 
of the BBB, and this effect could explain the significantly lower disease score in etomoxir-treated animals than in 
placebo-treated animals. Furthermore, based on observations by Pang and colleagues, blocking lipid metabolism 
by etomoxir could also have an effect on the level of ApoE and result in normalization of glucose metabolism in 
the brain. Clusterin has been found to be upregulated in acute and chronic plaques in MS52. A previous study 
indicated that clusterin could be a marker of neurodegeneration in AD and PD and that its expression is increased 
during progression of AD63. Moreover, clusterin and complement factors leak into the brain during BBB break-
down64. These findings raise the question of whether the significant reduction in the relative autoantibody reac-
tivity for clusterin in etomoxir-treated animals could be the result of reduced degradation of the BBB. Moreover, 
clusterin facilitates the removal of apoptotic cells and thus diminishes autoimmune responses following cell 
death65. The lower levels of serum anti-clusterin antibodies and the lesser degree of disease in etomoxir-treated 
animals at day 1 and day 5 could indicate that clusterin facilitates the clearance of apoptotic cells. Ji et al. found 
that SAP might have a protective role in the development of EAE66. In support of their findings, Grant and col-
leagues found that treatment with amyloid β−40 or amyloid β-42 peptides reduced motor paralysis and brain 
inflammation in four different EAE models67. Furthermore, Kurnellas et al. showed that amyloidogenic peptides 
such as tau, amyloid-β A4 and SAP had anti-inflammatory properties, reduced serum levels of interleukin-6 
and reduced paralysis in EAE68,69. This finding could indicate that the significant decrease in serum anti-SAP 
antibodies resulted in decreased inactivation of SAP and thereby a lesser degree of inflammation. A review by 
Levine indicated that serum albumin has two side effects in the brain70: anti-pathogenic properties because it is a 
target for ROS and pro-pathogenic properties because it is pro-inflammatory, and high levels of serum albumin 
can lead to seizure. Furthermore, serum albumin leaks into the brain during BBB breakdown and is taken up by 
macrophages and cleaved during the acute phase of MS. In most healthy individuals anti-albumin antibodies 
have been found71, and it was therefore expected to detect these antibodies in control animals. Interestingly, in the 
EAE-diseased animals anti-albumin antibodies were decreased. These results were validated by ELISA.
IFN-β-treated animals at days 1 and 5 had significantly lower serum concentrations of antibodies against com-
plement component C9 and gelsolin than the placebo group. An earlier study found a direct correlation between 
the level of complement component C9 and demyelination of the spinal cord in an EAE model55. The lower serum 
antibody reactivity for complement component C9 could indicate that it is more active, which would result in 
demyelination and thereby a high disease score in IFN-β-treated animals72. Gelsolin is involved in myelin wrap-
ping and is decreased in cerebrospinal fluid and serum in MS but elevated in brain tissue73,74. The low serum con-
centration of anti-gelsolin antibody could indicate that myelin wrapping in IFN-β-treated animals was affected. 
Furthermore, IFN-β-treated animals at days 1 and 5 had significantly higher serum concentrations of antibodies 
against PLP than placebo-treated animals, which is consistent with the higher disease score in IFN-β-treated ani-
mals. However, etomoxir-treated animals at day 5 also showed higher serum levels of antibodies against PLP than 
placebo-treated animals, highlighting a potential topic of interest for further investigation.
In conclusion, this study indicated that etomoxir is a more effective treatment for MBP-induced EAE than 
IFN-β and placebo, as it resulted in a significantly lower disease scores. Additionally, the results indicate that 
etomoxir-dependent inhibition of mitochondrial beta-oxidation in the EAE rat model is effective because of the 
regulation of serum autoantibodies against proteins such as ApoE, clusterin, SAP, and serum albumin, suggesting 
a role of these antigens in the progression of EAE and their potential use as diagnostic biomarkers for MS.
Materials and Methods
Experimental autoimmune encephalomyelitis rat model. Animal experiments were conducted 
according to NIH guidelines and were approved by the Danish National Committee for Ethics in Animal 
Experimentation (2015-15-0201-00647). Two-month-old female Lewis rats were obtained from Charles River 
Laboratories, Inc., Germany. The rats were housed under standardized conditions with 12 h light/dark cycles and 
free access to food and water. The rats were anesthetized with isoflurane (Baxter Laboratories) and then intrader-
mally injected in the base of the tail with an emulsion consisting of 100 µg of MBP (Sigma-Aldrich) suspended 
in saline and complete Freund’s adjuvant (Becton Dickinson) and supplemented with 0.2 µg of Mycobacterium 
tuberculosis (Becton Dickinson). EAE was induced in 45 rats, and five rats were used as controls and thus were not 
EAE-induced. Rats were treated daily with either etomoxir (Meta-IQ ApS, Denmark) or IFN-β (Extavia, Aalborg 
University Hospital, Denmark) on the first or fifth day of induction. Etomoxir was heated to 37 °C and dissolved 
in olive oil. Etomoxir was subcutaneously administered every day at a dosage of 1 mg/kg. Interferon-β was subcu-
taneously administered every other day at a dosage of 200,000 IU. The placebo group received daily injections of 
olive oil. All rats were weighed and clinically scored on a daily basis according to a scale from zero to five75: zero, no 
clinical signs of EAE; one, limp tail; two, paresis of one or two hind limbs; three, unilateral hind leg paralysis; four, 
bilateral hind leg paralysis; and five, bilateral hind leg paralysis and incontinence or moribund. Moreover, animals 
were not permitted to lose more than 20% body weight compared to their weight at the time of EAE induction. 
Rats were euthanized. Then, blood samples were obtained by cardiac puncture, and collected blood samples were 
labeled according to the groups. Blood samples were used for Western blot, ELISA and immunoprecipitation.
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Western blot. Preparation of rat brain sample. Cerebellum from three-week-old Sprague-Dawley rats was 
isolated, and protein homogenates were prepared by transferring the cerebellum to a dissection buffer containing 
10% sucrose (VWR), imidazole (Merck Millipore), EDTA (Sigma-Aldrich), Pefabloc (Sigma-Aldrich) and leu-
peptin (VWR). The mixture was homogenized (T10 basic ULTRA-TURAX homogenizer IKA®) for 20 sec; then, 
samples were centrifuged at 1000 g for 15 min. Supernatants were stored at −20 °C.
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Brain homogenate samples were diluted in dissection 
buffer. Then, sample buffer (Bio-Rad) and 5% beta- mercaptoethanol (Sigma-Aldrich) were added to the brain 
homogenate solution at a 1:1 ratio. Samples were incubated for 15 min at 65 °C. Precision Plus Protein Standard 
Ladder (Bio-Rad) was used as a reference. Western blots of total rat brain tissue were separated on 4–15% 
Mini-PROTEAN® TGX™ Precast Protein Gels (Bio-Rad) using a Mini-PROTEAN Tetra Cell system (Bio-Rad).
Blotting. Proteins were transferred to polyvinylidene fluoride membranes (Bio-Rad) by using a Trans-Blot 
Turbo Transfer System (Bio-Rad). Membranes were stained with 0.1% Ponceau S (MP Biomedicals; diluted in 
1% acetic acid (VWR) and Milli-Q water) for 10 min, and gels were stained with Coomassie (Sigma-Aldrich) for 
15 min. After washing three times in Milli-Q water, membranes and gels were respectively destained in 1% acetic 
acid in Milli-Q water for one hour and 10% ethanol, 7.5% acetic acid in Milli-Q water overnight, respectively. 
Membranes were cut vertically into lanes and blocked in 5% skimmed milk (VWR) diluted in 0.1% Tween- 20 
(Sigma-Aldrich) in PBS (PBS-T) for one hour on a table shaker at room temperature. Then, membranes were 
washed three times in PBS-T and incubated overnight on a table shaker at 4 °C with sera (1:100; diluted in 1% 
BSA, 0.1% NaN3 in PBS-T) from healthy rats or EAE-induced rats that received placebo, etomoxir or IFN-β. After 
washing three times in PBS-T, membranes were incubated with rabbit anti-rat secondary antibody conjugated 
with HRP (cat#61-9520, Thermo Scientific) diluted in 5% skimmed milk in PBS-T (1:1000) for one hour on a 
table shaker at room temperature. Membranes were washed three times in PBS-T and subsequently incubated in 
Amersham ECL Prime Western blot Detection Reagent (GE Healthcare) for 1 min. Membranes were then visual-
ized using an Odyssey Fc Imaging System (Li-Cor Biosciences) with LI-COR Image Studio™ software.
Indirect Enzyme-Linked ImmunoSorbent Assay. Wells were coated with a protein concentration of 
10 µg/ml of rat MBP (cat#2295, Sigma-Aldrich) or rat albumin (cat#A6414, Sigma-Aldrich) overnight at 4 °C. 
The coated wells were blocked by adding blocking buffer containing 0.1% Tween-20 (Sigma-Aldrich) and 5% 
skimmed milk (VWR) in PBS, and incubated for one hour at room temperature. The wells were washed three 
times in PBS. Afterwards, serum samples diluted in blocking buffer (1:100) were added and incubated for one 
hour at room temperature. At the same time, standards were prepared in a range of 1:10 to 1:100000 using rat 
anti-MBP (cat#ab7349, Abcam) and rabbit anti-albumin (cat#ab207327, Abcam) antibodies diluted in blocking 
buffer and incubated for one hour at room temperature. All samples and standards for MBP were run in triplicates 
and in duplicates for albumin. After incubation, all wells were washed three times in PBS. Secondary antibodies, 
rabbit anti-rat conjugated with HRP (cat#61-9520, Thermo Scientific) and goat anti-rabbit conjugated with HRP 
(cat#P0448, Dako) diluted in blocking buffer (1:2000), were added and incubated for one hour at room tempera-
ture. All wells were washed four times in PBS and then 3,3′5,5′-tetramethylbenzidine (Sigma-Aldrich) were added 
and incubated for 15 min at room temperature. Following incubation, stop solution containing MilliQ-water and 
2 M H2SO4 (1:1) were added. Subsequently, the optical density was read at 450 nm using EnSpire Multimode Plate 
Reader. The concentration of autoantibodies was calculated using the standard curves in GraphPad Prism 7.
Immunoprecipitation. Preclearing. A mixture of antibody buffer containing 1% BSA, 0.1% 2 M NaN3 in 
PBS-T and A/G magnetic beads (Pierce Protein Biology, Thermo Scientific) was prepared and transferred to a 
tube in a magnetic stand. Then, the supernatant was discarded, and the magnetic beads were collected. Antibody 
buffer was added to the magnetic beads mixture and vortexed. The mixture was then added to brain homogen-
ate obtained from cerebellum of a three-week-old Sprague-Dawley rat and incubated on ice for one hour. Next, 
this solution was transferred to the magnetic stand, and the beads were collected, washed three times in anti-
body buffer and subsequently stored at 4 °C. The supernatant was collected, and additional magnetic beads were 
added and incubated on ice for 30 min. This step was repeated three times, and antibody buffer was added to the 
supernatant.
Immunoprecipitation. A total of 1 µl of serum from healthy rats and EAE-induced rats receiving placebo, etomoxir 
or IFN-β, was used for immunoprecipitation experiments. Precleared brain homogenate, which was the same for all 
groups, was mixed with serum from EAE animals and incubated on ice for one hour. Magnetic beads were added to 
each sample and incubated on ice for one hour. After incubation, samples were placed in a magnet stand to isolate 
the beads, which were washed three times in antibody buffer and then eluted by incubating in 120 mM sodium 
deoxycholate (SDC) in 50 mM triethylammonium bicarbonate (TEAB) (pH 8.5) for 10 min at 95 °C.
Proteomics sample preparation. Proteomic sample preparation was performed according to a FASP 
digestion protocol by Bennike et al., in which samples are prepared with ethyl acetate phase inversion to facilitate 
surfactant removal76. The eluate was transferred to individual YM-10 kDa spin filters for digestion (Millipore, 
Billerica, MA, USA) and centrifuged at 14,000 g for 15 min at room temperature, which were the settings for all 
future performed centrifugation steps. Protein disulfide bonds were reduced with 12 mM tris(2-carboxyethyl)
phosphine (Thermo Scientific) and alkylated with 50 mM chloroacetamide (Sigma-Aldrich) for 30 min at 37 °C, 
followed by centrifugation. Reducing and alkylating agents were dissolved in 120 mM SDC/50 mM TEAB 
(pH 8.5). In preparation for digestion, 10 mM CaCl and 50 mM TEAB buffer was added to the spin filter and 
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centrifuged. A 1:25 (w/w) chymotrypsin:protein ratio dissolved in digestion buffer was added to the spin filter, 
and the samples were digested overnight at 37 °C. Flow-through, containing the peptides, was retrieved by addi-
tion of 50 mM TEAB buffer and centrifugation. To facilitate SDC removal, a phase separation was performed 
with 3:1 (v/v) ethyl acetate:sample and acidified by addition of trifluoroacetic acid (TFA) to a final concentration 
of 0.5%. Total phase separation was achieved by 2 min agitation followed by centrifugation. The aqueous phase 
was collected and vacuum centrifuged overnight, and the dry peptide product was stored at −80 °C until analysis.
Mass spectrometry analysis. Peptides were resuspended in a solution containing 2% acetonitrile (ACN), 
0.1% formic acid (FA) and 0.1% TFA, and then, peptides were briefly sonicated. Five micrograms of total peptide 
material were analyzed per liquid chromatography–mass spectrometry analysis. Samples were analyzed using a 
UPLC-nanoESI MS/MS setup with a NanoRSLC system (Dionex). The system was coupled online with an emitter 
for nanospray ionization (New Objective PicoTip 360-20-10) to a Q Exactive HF mass spectrometer (Thermo 
Scientific). The peptide material was loaded onto a 2-cm trapping reversed-phase Acclaim PepMap RSLC C18 
column (Dionex) and separated using an analytical 75-cm reversed-phase Acclaim PepMap RSLC C18 column 
(Dionex). Both columns were kept at 60 °C. The sample was eluted with a gradient of 90% solvent A (0.1% FA, 
0.1% TFA) and 10% solvent B (0.1% FA, 0.1% TFA in ACN), which was increased to 7% solvent B on a 1-min 
ramp gradient at a constant flow rate of 300 nL/min. Subsequently, the gradient was raised to 30% solvent B on a 
45-min ramp gradient. The mass spectrometer was operated in positive mode, selecting up to 20 precursor ions 
with a mass window of m/z 1.6 based on highest intensity for higher-energy collisional dissociation (HCD) frag-
menting at a normalized collision energy of 27. Selected precursors were dynamically excluded for fragmentation 
for 30 sec.
Protein identification and quantitation analysis. A label-free relative quantitation analysis was per-
formed using MaxQuant 1.5.7.4 software. Raw files were searched against the Rattus norvegicus UniProt data-
base (proteome ID UP000002494)77,78. All standard settings were employed with carbamidomethylation (C) as a 
static peptide modification and deamidation (NQ), oxidation (M), formylation (N-terminal and K), and protein 
acetylation (N-terminal) as variable modifications. The output contained a list of proteins identified below 1% 
false discovery rate, and their abundances were further filtered and processed using Perseus v1.5.6.0 platform. All 
reverse hits that identified proteins were removed from further analysis, and the data were log2-transformed in 
order to approximate normal distribution. Two or more unique peptides were required for protein quantitation. 
Additionally, a non-zero quantitation value in at least 70% of the samples in one of the groups was required for 
the quantifiable proteins. A Venn diagram was generated using FunRich software to compare the number of 
proteins that were present in 70% of the samples in each group79. The mass spectrometry proteomics data have 
been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier 
PXD00883580,81.
Applied statistics. Disease score data were analyzed by unpaired t-tests. ELISA data were quantified by 
interpolating samples according to a standard curve and groups were analyzed by one-way ANOVA. Quantifiable 
proteins identified in the different groups were compared in a Venn diagram, and to investigate differences in the 
expression of proteins between the groups, unpaired two-tailed t-tests were performed. All data are presented as 
the mean ± SEM. P values of 0.05 were used as a cut-off.
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